Liver Metastases
259
57
74
92
Key Insights
Highlights
Success Rate
81% trial completion
Published Results
25 trials with published results (10%)
Research Maturity
92 completed trials (36% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
8.1%
21 terminated out of 259 trials
81.4%
-5.1% vs benchmark
10%
26 trials in Phase 3/4
27%
25 of 92 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 92 completed trials
Clinical Trials (259)
Neoantigen Dendritic Cell Vaccine and Nivolumab in HCC and Liver Metastases From CRC
Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis
CT Volumetry and Hepatic Vascular Deformation Mapping to Predict Post-Hepatectomy Liver Failure
DRAGON Registry - International Multicenter Registry and Medical Image Bank for Patients With Primarily Unresectable Liver Cancer or Liver Metastases That Underwent Combined Portal and Hepatic Vein Embolization (PVE/HVE) to Increase Future Liver Remnant Before Resection.
Hepatic Artery Infusional Floxuridine to Treat Pancreatic Cancer Liver Metastases
ctDNA-Directed Post-Hepatectomy Chemotherapy for Patients With Resectable Colorectal Liver Metastases
SBRT + PD-1 Monoclonal Antibody in Unresectable Colorectal Liver Metastases
French Assessment of MRD by Liquid Biopsies in Colorectal With Liver Metastasis Patients (FRENCH.MRD.CRLM)
Alpha Radiation Emitters Device (DaRT) for the Treatment of Liver Metastases
OAR-Based, Dose Escalated SBRT With Real Time Adaptive MRI Guidance for Liver Metastases
Proton Therapy in the Treatment of Liver Metastases
Liver Transplantation for Non-resectable Colorectal Liver Metastases: Translational Research
China Metastatic Liver Cancer Clinical Registry Cohort Database
Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases
SAMe in Prevention of Oxaliplatin-associated Liver Injury
Neoadjuvant Dupilumab and Toripalimab in MSS CRC Subjects With Resectable Liver Metastases
Incremental Value of Magnetic Resonance Imaging in Selection of Pancreatic Cancer Patients for Surgery
Outcomes After Liver and Biliary Resection at a High-Volume Center
Comparison of Contrast Agents in Liver Magnetic Resonance (MR) for the Detection of Hepatic Metastases
Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients